Search the Newsreel

Pediatrix Medical Group (MD) awards 472-share equity grant to director

Pediatrix Medical Group (MD) director Shirley A. Weis was granted 472 restricted shares of common stock on August 12, 2026, under the company's 2008 Incentive Compensation Plan. These shares, valued at $26.50 each, will vest on May 7, 2027, and increase Weis's direct holdings …

Pediatrix Medical Group (MD) director receives 472-share restricted stock grant

John M. Starcher Jr., a director at Pediatrix Medical Group (MD), was granted 472 restricted shares of common stock on August 12, 2026. These shares, valued at $26.50 each, are part of the company's incentive compensation plan and will vest on May 7, 2027. …

Pediatrix Medical Group (MD) director awarded 472 restricted shares and reports trust holdings

Pediatrix Medical Group director Thomas McEachin was granted 472 restricted shares of common stock on August 12, 2026, valued at $26.50 per share, under the company's incentive plan. These shares will vest on May 7, 2027. Following this transaction, his direct holdings increased to …

Pediatrix Medical Group (MD) grants 472 restricted shares to director Sansone

Pediatrix Medical Group (MD) director Guy P. Sansone received an equity award of 472 restricted shares on August 12, 2026, priced at $26.50 per share. These shares, granted under the company's Second Amended and Restated 2008 Incentive Compensation Plan, will vest on May 7, …

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Report - Results, Call & Slides

Walchandnagar Industries Q1 Results: Net profit turns positive at ₹118 lakh

Pediatrix Medical Group, Inc. Stock 12‑Month Price Target Cut to $26, Implies 2% Downside

The average 12-month price target for Pediatrix Medical Group, Inc. (MD) stock has been lowered from $26.17 to $26 by 5 analysts, with a range of $21 to $28 per share. This new target suggests a potential 2% downside from the August 12 closing …

Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Wasatch Advisors LP Boosts Stake in Pediatrix Medical Group, Inc. $MD

Wasatch Advisors LP increased its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 21.9% in the second quarter, holding 2.50 million shares valued at approximately $63.3 million. Institutional investors now own 97.71% of the company's stock, which recently reported strong quarterly earnings, beating revenue …

Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Mark Ordan Chief Financial Officer - Kasandra Rossi Full Conference Call Transcript Operator: Thank you for standing by. My name is Jordan, and I'll …

Walchandnagar Industries turns profitable in Q1FY26 on 83% revenue surge

Walchandnagar Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Pediatrix Medical Group (MD) Stock Seems Undervalued While Its 89% Return Raises Questions

Pediatrix Medical Group (MD) has seen an 89% share price return over the past year, yet its stock appears undervalued based on several valuation metrics, including a P/E ratio significantly below the healthcare sector average. Despite a recent share price drop post-earnings, the company …

Is Stronger Q2 2026 EPS From Operations Altering The Investment Case For Pediatrix Medical Group (MD)?

Pediatrix Medical Group (MD) reported stronger Q2 2026 results with increased sales and net income, leading to improved EPS from continuing operations. These results, along with the company's inclusion in Russell 2000 Defensive indexes, support its investment narrative of disciplined cost control in the …

Sei Investments Co. Cuts Stock Holdings in Pediatrix Medical Group, Inc. $MD

Sei Investments Co. reduced its stake in Pediatrix Medical Group Inc. (NYSE:MD) by 19.3% in the first quarter, selling 37,564 shares and retaining 157,407 shares valued at $3.37 million. Despite institutional selling and buying from various firms, the company reported strong Q1 earnings of …

Ginkgo Bioworks (NYSE:DNA) Stock Rating Upgraded by Wall Street Zen

Ginkgo Bioworks Q2 Earnings Call Highlights

Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …

Biosecurity sale shapes Ginkgo Bioworks (NYSE: DNA) Q2 2026 results

Ginkgo Bioworks reported a significant decrease in Q2 2026 revenue from continuing operations, down to $20.156 million from $39.134 million a year prior, primarily due to reduced program scope with key agriculture and pharmaceutical clients. Despite a sizable operating loss from continuing operations, the …

Ginkgo Bioworks Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:DNA) 2026-08-06

Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …

Earnings call transcript: Ginkgo Bioworks Q2 2026 revenue miss weighs on shares

Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …

Informe de resultados de Ginkgo Bioworks: los ingresos del Q2 2026 decepcionan

Ginkgo Bioworks (NYSE:DNA) Releases Earnings Results, Beats Expectations By $0.15 EPS

Ginkgo Bioworks (NYSE: DNA) posts Q2 loss, wins $47M lab deal

Insiders At Pediatrix Medical Group Sold US$1.8m In Stock, Alluding To Potential Weakness

This article analyzes insider selling at Pediatrix Medical Group (NYSE:MD) totaling US$1.8m over the last year, particularly a large sale by the CEO, which could signal potential weakness in the company's future performance. Despite the stock price being down 23% in the past 12 …

Ginkgo Bioworks earnings beat by $0.13, revenue fell short of estimates

Pediatrix Q2 2026 earnings: Reimbursement gains offset volume declines

Pediatrix Medical Group (NYSE: MD) reported a 4.0% year-over-year increase in Q2 2026 net revenue to $487.8 million, driven by recent acquisitions and improved reimbursement rates, despite a decline in patient volumes. While diluted GAAP EPS rose to $0.49, higher operating costs led to …

Pediatrix Medical Group’s (NYSE:MD) Q2 CY2026: Beats On Revenue But Stock Drops 12.3%

Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 results that exceeded revenue and non-GAAP profit expectations, with sales up 4% year-on-year to $487.8 million and adjusted EPS of $0.63. Despite beating estimates, the stock dropped 12.3% post-announcement, indicating investor disappointment. The company highlighted strong performance …

Pediatrix Medical beats Q2 revenue estimates, reaffirms 2026 adjusted EBITDA outlook

Pediatrix Medical Group (NYSE: MD) reported Q2 revenue that beat analyst estimates, driven by recent acquisitions and improved reimbursement factors, despite a decrease in patient volumes. The company also reaffirmed its 2026 full-year Adjusted EBITDA outlook. Analysts currently rate the stock as a "buy" …

Earnings Flash (MD) Pediatrix Medical Group, Inc. Posts Q2 Adjusted EPS $0.63 per Share, vs. FactSet Est of $0.59

Pediatrix Medical Group, Inc. (MD) reported Q2 adjusted EPS of $0.63 per share, surpassing FactSet's estimate of $0.59. The article provides a snapshot of the company's recent performance and mentions its Q2 2026 earnings call scheduled for August 4, 2026. Further details about the …

MEDNAX ($MD) Releases Q2 2026 Earnings

Pediatrix Medical Group (NYSE:MD) Issues Quarterly Earnings Results

Pediatrix Medical Group (MD) Q2 Earnings: What To Expect

Pediatrix Medical Group (MD) is set to report its Q2 earnings this Tuesday. The market expects a 1.9% year-on-year revenue growth, a turnaround from last year's decrease. The company has a strong track record of beating revenue estimates, and analysts have reconfirmed their expectations …

Pediatrix Medical Group Inc (MD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pediatrix Medical Group Inc (MD), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MD's current stock price is trading between resistance at $28.32 and support at $24.25, suggesting suitability for …